Biocidium is a private biopharmaceutical company focused on the discovery and development of therapies to treat serious bacterial and fungal infections, as well as certain cancers and skin disorders.

The company’s lead candidate, BCM-0184, is a novel bio-based molecule discovered in house that is being developed in both oral and topical formulations for a variety of indications.

Biocidium’s primary focus is advancing BCM-0184 as an antibiotic due to its demonstrated rapid bactericidal in vitro activity against both gram-positive and gram-negative pathogens, including key multi-drug resistant bacteria, and positive preclinical safety study results.

BCM-0184 has also shown in vitro efficacy against susceptible and multi-drug resistant fungi, and potential for the treatment of skin cancers, psoriasis and eczema.